Role of Fibrates and HMG-CoA Reductase Inhibitors in Gallstone Formation |
| |
Authors: | Francois-Xavier Caroli-Bosc Philippe Le Gall Pascal Pugliese Benoit Delabre Corinne Caroli-Bosc Jean-Francois Demarquay Jean-Pierre Delmont Patrick Rampal J.C. Montet |
| |
Affiliation: | Federation of Digestive Diseases, Archet II Hospital, University of Nice-Sophia, Antipolis, France. |
| |
Abstract: | Fibrate derivatives and HMG-CoA reductase inhibitors modify homeostasis of cholesterol. The aim of this study was to assess in an unselected population whether these hypolipidemic drugs are risk factors for cholelithiasis or, conversely, are protective agents. Both sexes, all socioeconomic categories, pregnant women, and cholecystectomized subjects were included. Clinical data collection and gallbladder ultrasonography were both carried out in a double-blind fashion. Fibrate derivatives were predominantly fenofibrate, HMG-CoA reductase inhibitors were simvastatin and pravastatin. On univariate analysis, age (>50 years), sex, and use of fibrates were found to be significantly related to the presence of cholelithiasis. Age, sex, and fibrate treatment remained independently correlated with the presence of gallstones on multivariate analysis. With fibrates, the relative risk for lithiasis was 1.7 (P = 0.04). The HMG-CoA reductase inhibitors were not associated with a protective effect on univariate analysis. Of the lipid-lowering drugs, only fibrate derivatives were found to increase the risk of gallstone formation. |
| |
Keywords: | gallstones HMG-CoA reductase inhibitors fibrates |
本文献已被 PubMed SpringerLink 等数据库收录! |
|